Introduction: The Search for Better Cancer Markers

Colorectal cancer (CRC) is one of the most common cancers worldwide, ranking among the leading causes of cancer-related deaths. While advances in surgery and targeted therapies have improved survival rates, cancer recurrence and metastasis remain major challenges. Researchers are constantly searching for new biomarkers—molecules that can help predict cancer progression, improve diagnosis, and guide treatment decisions.

A recent study published in Scientific Reports suggests that a protein called Integrin beta5 (ITGB5) could be a key player in colorectal cancer progression. Not only is ITGB5 highly expressed in CRC, but it also appears to drive tumor growth and metastasis through the Wnt signaling pathway, a well-known regulator of cancer development. Could ITGB5 become a new target for therapy?

What is ITGB5?

ITGB5 is a protein that helps cells stick to their surroundings. Normally, it plays a role in cell adhesion and communication, which are crucial for healthy tissue structure. However, in cancer, ITGB5 is hijacked by tumor cells, allowing them to grow uncontrollably, break away from the primary tumor, and invade other tissues.

How ITGB5 Promotes Colorectal Cancer Progression

1. ITGB5 is Overexpressed in CRC

Researchers analyzed data from the Gene Expression Omnibus (GEO) database and confirmed that ITGB5 is significantly upregulated in colorectal cancer tissues compared to normal tissues. High ITGB5 levels were also linked to advanced tumor stage, deeper invasion, lymph node metastasis, and distant metastasis—all indicators of aggressive disease.

2. ITGB5 Activates the Wnt Signaling Pathway

One of the key discoveries of this study is that ITGB5 fuels cancer growth by activating the Wnt/β-catenin signaling pathway. The Wnt pathway is like a master switch that controls cell division and movement. When it is overactive, cancer cells gain the ability to grow rapidly, resist treatment, and spread to other organs.

By blocking ITGB5 expression in CRC cells, researchers observed a reduction in tumor cell proliferation, invasion, and migration, confirming that ITGB5 plays a direct role in driving colorectal cancer progression.

3. ITGB5 is Linked to Immune Cell Infiltration

The study also found that high ITGB5 expression is associated with changes in immune cell populations within the tumor microenvironment. ITGB5-positive tumors had more M0 and M2 macrophages, immune cells that can suppress the body’s natural anti-cancer response and promote tumor growth. This suggests that ITGB5 may help tumors evade immune surveillance, making it even harder for the body to fight the cancer.

Can ITGB5 Be Used as a Prognostic Marker?

Since ITGB5 expression correlates with tumor stage and patient survival, researchers investigated its potential as a biomarker for predicting disease outcome.

• Patients with high ITGB5 levels had worse overall survival (OS) and disease-free survival (DFS) compared to those with lower levels.
• ITGB5 expression outperformed traditional staging methods (like TNM staging) in predicting patient prognosis.

These findings suggest that measuring ITGB5 levels in patients could help doctors identify high-risk individuals who may require more aggressive treatment or closer monitoring.

Could Targeting ITGB5 Lead to New Treatments?

Since ITGB5 appears to drive tumor growth and immune suppression, blocking its function could be a promising strategy for new colorectal cancer therapies. Potential treatment approaches could include:

• Small molecules or antibodies that block ITGB5 activity, preventing cancer cells from spreading.
• Drugs that target the Wnt/β-catenin signaling pathway, cutting off a key survival mechanism of ITGB5-positive tumors.
• Immunotherapy combinations that counteract ITGB5’s effect on immune cells, restoring the body’s natural ability to fight cancer.

While more research is needed, these findings open the door for future clinical studies to test whether ITGB5 inhibitors could improve treatment outcomes in colorectal cancer patients.

Conclusion: A Promising Step Forward

The discovery of ITGB5 as a key driver of colorectal cancer progression and metastasis provides new insight into how tumors grow and spread. Not only does ITGB5 serve as a potential biomarker for prognosis, but it also represents a new target for therapy.

As researchers continue to explore ways to block ITGB5’s cancer-promoting effects, this discovery could pave the way for more precise and effective colorectal cancer treatments in the future.

Source

https://www.nature.com/articles/s41598-025-93081-7
Chen, Z., Fang, Y., Zhong, S., Lin, S., Yang, X., & Chen, S